Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of tocilizumab mono-therapy in patients with large vessel vasculitis (LVV; giant cell arteritis or Takayasu arteritis) and polymyalgia rheumatica (PMR)

Trial Profile

Efficacy and safety of tocilizumab mono-therapy in patients with large vessel vasculitis (LVV; giant cell arteritis or Takayasu arteritis) and polymyalgia rheumatica (PMR)

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Giant cell arteritis; Polymyalgia rheumatica; Takayasu syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Oct 2018 104-Week results (n=12) in patients with Large Vessel Vasculitis, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 06 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 12 Oct 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top